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OBJECTIVES We sought to prospectively compare the prognostic value of cardiac iodine-123 (I-123)
metaiodobenzylguanidine (MIBG) imaging with that of heart rate variability (HRV) in
patients with mild-to-moderate chronic heart failure (HF).
BACKGROUND Cardiac I-123 MIBG imaging, which reflects cardiac adrenergic nerve activity, provides
prognostic information on chronic HF patients. Reduced HRV, indicating derangement in
cardiac autonomic control, was also reported to be associated with a poor prognosis in chronic
HF patients.
METHODS At study entry, I-123 MIBG imaging and 24-h Holter monitoring were performed in 65
chronic HF outpatients with a radionuclide left ventricular ejection fraction 40%. The
cardiac MIBG heart to mediastinum ratio (H/M) and washout rate (WR) were obtained from
MIBG imaging. The time and frequency domain parameters of HRV were calculated from
24-h Holter recordings.
RESULTS At a mean follow-up of 34  19 months, WR (p  0.0001), H/M on the delayed image (p
 0.01), and normalized very-low-frequency power (n-VLFP) (p  0.047) showed a
significant association with the cardiac events (sudden death in 3 and hospitalization for
worsening chronic HF in 10 patients) on univariate analysis. Multivariate analysis revealed
that WR was the only independent predictor of cardiac events, although the predictive
accuracy for the combination of abnormal WR and n-VLFP significantly increased,
compared with that for abnormal WR (82% vs. 66%, p  0.05).
CONCLUSIONS Cardiac MIBG WR has a higher prognostic value than HRV parameters in patients with
chronic HF. The combination of abnormal WR and n-VLFP would be useful to identify
chronic HF patients at a higher risk of cardiac events. (J Am Coll Cardiol 2003;41:231–8)
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In chronic heart failure (HF), abnormalities in cardiac
autonomic control, characterized by sympathetic overactiv-
ity and parasympathetic withdrawal (1), contribute to the
progression of the disease and are associated with an
unfavorable prognosis (2,3). Therefore, assessing cardiac
autonomic status is clinically important in the management
of patients with chronic HF. Heart rate variability (HRV)
analysis is proposed as a noninvasive tool for the assessment
of cardiac autonomic regulation (4) and has been shown to
predict the clinical outcome in patients with chronic HF
(5–9). On the other hand, cardiac adrenergic nerve activity
has been estimated using iodine-123 (I-123) metaiodoben-
zylguanidine (MIBG) as a noradrenaline analogue (10,11).
It has been reported that cardiac MIBG imaging provides
prognostic information on patients with chronic HF (12–
15). Although some investigators have examined the rela-
tionship between the parameters in cardiac MIBG imaging
and HRV analysis in patients with chronic HF (16–18), no
information is available on the comparison of the prognostic
value of cardiac MIBG imaging and HRV analysis in
chronic HF. The aim of this study was to prospectively
compare the prognostic value of cardiac MIBG imaging
with that of HRV in patients with chronic HF.
METHODS
Study patients. We studied 71 consecutive chronic HF
outpatients in sinus rhythm, whose radionuclide left ven-
tricular ejection fraction (R-LVEF) was 40%. Patients
were required to be stable for at least three months by use of
conventional therapy with angiotensin-converting enzyme
inhibitors, diuretics, and digoxin. Patients were excluded
from the study if they had atrial fibrillation, sinus node
dysfunction, atrioventricular block, a permanent pacemaker,
significant renal dysfunction, insulin-dependent diabetes
mellitus, or autonomic neuropathy. None of the patients
were receiving beta-blockers, calcium antagonists, or anti-
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arrhythmic drugs, except for mexiletine (n  10) and
amiodarone (n  3) at study enrollment. At study entry, all
patients had cardiac MIBG imaging, 24-h ambulatory
ECG monitoring, echocardiography, and a plasma nor-
adrenaline assay. All patients gave written, informed con-
sent for their participation in this study, which was ap-
proved by the Osaka Prefectural General Hospital’s Review
Committee.
Radionuclide angiography for entry criteria. Before en-
tering this study, patients underwent electrocardiography
(ECG)-gated blood-pool scintigraphy at rest in the supine
position, using a conventional rotating gamma camera
(Prism 2000, Picker, Bedford, Ohio) equipped with a
low-energy, high-resolution, parallel-hole collimator. Pa-
tients were given 740 MBq of technetium-99m–labeled
human serum albumin (Nihon Medi-Physics, Nishinomia,
Japan). The camera was positioned in the modified left
anterior oblique projection to isolate the left ventricle (LV)
from other cardiac structures, and data acquisition was then
completed. The LVEF was calculated using a standard
program (19).
Cardiac MIBG imaging. No patients were taking tricyclic
antidepressant drugs, sympathomimetic agents, or other
drugs known to interfere with MIBG uptake in the month
preceding cardiac MIBG imaging.
CARDIAC MIBG ACQUISITION. All patients underwent myo-
cardial imaging with I-123 MIBG (Daiichi Radioisotope
Laboratory, Tokyo, Japan), using the same gamma camera as
for the radionuclide angiography. Patients were placed in the
supine position. A 111-MBq dose of I-123 MIBG was
injected intravenously at rest after an overnight fast. Initial and
delayed image acquisitions were performed in the anterior
chest view 20 and 200 min after the isotope injection.
IMAGE ANALYSIS. Two independent observers who were
unaware of the clinical status of patients assessed cardiac
MIBG uptake (Fig. 1). Left ventricular activity was re-
corded using a manually drawn region of interest (ROI)
over the whole LV myocardium, and the mean heart counts
per pixel were calculated. Another 7  7 pixel ROI was
recorded over the upper mediastinal area, and the mean
counts per pixel were calculated. Background subtraction
was performed using the upper mediastinal ROI. The
heart-to-mediastinum ratio (H/M) was then determined by
dividing the mean counts per pixel in the LV by the mean
counts per pixel in the mediastinum. After taking radioac-
tive decay of I-123 into consideration, the cardiac MIBG
washout rate (WR) was calculated from the initial and
delayed images, as previously reported (15). Based on our
previous study, abnormal WR was defined as more than
27% (15).
24-h ambulatory ECG monitoring. Patients underwent
24-h dual-channel ambulatory ECG recording with a Mar-
quette Electronics (Milwaukee, Wisconsin) 8000 Holter
monitoring system. Recordings were analyzed by two inde-
pendent observers who were blinded to the clinical status of
the patients. Recordings with more than 15% noise or
ectopic beats during 24 h and those with 20 h of
analyzable data were excluded from this analysis. Ventricu-
lar arrhythmias were classified according to Lown’s grade,
and nonsustained ventricular tachycardia was defined as five
or more consecutive premature ventricular beats, each last-
ing 30 s.
Traditional measurements of HRV were analyzed using
the HRV system, DSC-3100;MemCalc/Chiram (Nihon
Koden Co. Ltd., Tokyo, Japan), according to the Task
Force of the European Society of Cardiology and the North
American Society of Pacing and Electrophysiology (4).
Time domain analysis of HRV included the mean RR
(mean duration of all normal to normal [NN] intervals),
SDNN (standard deviation of all NN intervals), SDANN
(standard deviation of the averages of NN intervals in all
5-min segments), SDNN index (mean of the standard
deviations of all NN intervals for all 5-min segments),
rMSSD (square root of the mean of the sum of the squares
of differences between adjacent NN intervals), pNN50
(number of NN intervals differing by more than 50 ms from
the adjacent interval divided by the total number of NN
intervals), and HRV triangular index. Spectral analysis was
performed using the maximum entropy method (20). Power
spectra were quantified by the area within the following
frequency band: total power (0.0001 to 0.5 Hz), ultra-low-
frequency power (ULFP: 0.0001 to 0.003 Hz), very-low-
frequency power (VLFP: 0.003 to 0.04 Hz), low-frequency
power (LFP: 0.04 to 0.15 Hz), and high-frequency power
(HFP: 0.15 to 0.4 Hz). The LFP/HFP ratio was also
calculated. The power within each band was also expressed
as the percentage of the total power (normalized ULFP,
VLFP, LFP, and HFP). We determined a control value for
the HRV parameter in 20 persons (12 men and 8 women;
mean age 55  12 years) who had no history of heart
disease, a normal physical examination, and normal ECG
and chest X-ray findings. The mean value of normalized
VLFP (n-VLFP) was 32.3  5.1%. Therefore, we defined
abnormal n-VLFP as 22%, which is the mean control
value 2 SD.
Echocardiography. Two-dimensional echocardiography
was performed with a Toshiba SSH-380A recorder
equipped with a 2.5- or 3.75-MHz transducer. The stan-
dard technique was employed for sizing the LV and atrium
Abbreviations and Acronyms
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H/M  heart to mediastinum ratio
HRV  heart rate variability
I-123  iodine-123
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(21). The LV dimension was measured at end-diastole on
the R-wave of the ECG-derived QRS complex, just below
the level of the mitral leaflets through the standard left
parasternal window. The left atrial dimension (LAD) was
measured as the distance from the leading edge of the
posterior aortic wall to the leading edge of the posterior left
atrial wall at end-systole.
Plasma noradrenaline concentration. Blood sampling for
determination of the plasma noradrenaline concentration
was done from an intravenous cannula after resting for at
least 30 min in the supine position. The plasma noradren-
aline concentration was determined in EDTA plasma by
high-performance liquid chromatography (22) at Shionogi
Biomedical Laboratories (Osaka, Japan). A duplicate deter-
mination in the laboratory showed a coefficient of variation
of 0.4% to 5.5%.
Follow-up. All of the study patients were then followed up
in our hospital at least once a month by clinicians who did
not know the results of the cardiac MIBG imaging and
HRV analysis. The end point of this study was when a
patient died either suddenly or from other cardiac diseases,
or hospital admission for worsening HF failure.
Statistical analysis. Data are presented as the mean value
 SD. The Student t test and a Fisher exact test were used
to compare differences for continuous and discrete variables,
respectively, in patients with and without cardiac events.
The cardiac event–free rates in the two groups were calcu-
lated using the Kaplan-Meier method, and the difference
between them was detected using the log-rank test. The
Cox proportional hazards regression model was used to
determine the significance of variables predictive of outcome
by univariate analysis (p  0.05) as independent predictors
of cardiac events on multivariate analysis. The Fisher exact
test was used to compare sensitivity, specificity, predictive
accuracy, and positive and negative predictive values among
the different criteria for prediction of cardiac events. All
statistical analyses were carried out using the Stat-View
statistical package, version 4.5. A p value 0.05 was
considered statistically significant.
RESULTS
Characteristics of patients. Of 71 enrolled patients, six
were excluded: five because of the presence of15% ectopic
beats or noise during 24-h ambulatory ECG monitoring
and one because of the recording of 20 h of analyzable
data. Thus, analysis of both HRV and cardiac MIBG
imaging was possible in 65 patients. The mean age of the 65
patients was 63  12 years (range 28 to 85). Fifty-one
patients (79%) were men and 14 (21%) were women.
Radionuclide LVEF was 28  8%; 13 patients (20%) were
in functional class I, 38 patients (58%) were in class II, and
14 patients (22%) were in functional class III. Heart failure
was due to ischemic heart disease in 41 patients (63%) and
due to idiopathic dilated cardiomyopathy in 24 patients
(37%).
Follow-up outcome. All patients were followed up com-
pletely. The mean period of follow-up was 34 months
Figure 1. Iodine-123 metaiodobenzylguanidine (MIBG) imaging in a patient with chronic heart failure (HF). Heart (H) and mediastinum (M) were
selected, as shown, to measure the H/M ratio. The cardiac MIBG washout rate (WR) was calculated from the initial (left) and delayed images (right).
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(maximum 57 months). All patients were examined at least
once a month in our hospital during a study period. During
that period, 13 (20%) of 65 patients had cardiac events.
Three patients died suddenly, 10 patients were admitted for
worsening chronic HF, and one of these patients subse-
quently died of progressive pump failure.
Comparison of baseline characteristics between patients
with and without cardiac events. The baseline character-
istics of patients with and without cardiac events are listed in
Table 1. There were no differences in age, gender, or
functional class between the two groups. Although there
were no significant differences in the 6-min walk distance,
heart rate, blood pressure, R-LVEF, LV end-diastolic
dimension, Lown’s grade, or presence of nonsustained
ventricular tachycardia between the two groups, the LAD
was significantly greater and the plasma noradrenaline
concentration was significantly higher in patients with than
in those without the cardiac events.
There was also no significant difference in drug use
between patients with and without cardiac events. As for
beta-blockers, 22 of 65 study patients received carvedilol just
after study entry. There were no significant differences in
the number of patients receiving beta-blockade just after
study entry (23% [3/13] vs. 37% [19/52], p 0.51) or at the
last follow-up (31% [4/13] vs. 56% [29/52], p  0.13)
between the two groups. The mean dose of carvedilol in
patients with events was similar to that in patients without
events (15.0  5.8 vs. 15.7  5.9 mg/day).
Figure 2 shows the results of cardiac MIBG imaging.
Patients with cardiac events had a significantly lower H/M
ratio on the delayed image (1.56  0.29 vs. 1.77  0.28, p
 0.02) and a higher WR (44.0  14.7% vs. 25.6  12.8%,
p  0.0001) than those without cardiac events, although
there was no significant difference in H/M on the early
image between the two groups (1.80  0.30 vs. 1.85 
0.26). The results of HRV parameters in patients with and
without cardiac events are listed in Table 2. Patients with
cardiac events had significantly lower n-VLFP than did
Table 1. Clinical and Study Characteristics in Patients With
Chronic Heart Failure in Relation to Cardiac Events
With
Events
(n  13)
Without
Events
(n  52) p Value
Age (yrs) 61  16 64  10 NS
Gender (male) 77% 79% NS
Ischemic heart disease 46% 67% NS
NYHA functional class 2.1  0.8 2.0  0.6 NS
6-min walk distance (m) 355  86 368  94 NS
Heart rate (beats/min) 74  15 76  10 NS
Systolic blood pressure
(mm Hg)
122  15 130  18 NS
Diastolic blood pressure
(mm Hg)
76  13 73  8 NS
LVEF (%) 26  8 29  8 NS
Ventricular tachycardia (%) 15% 21% NS
Lown’s grade 3.8  0.7 3.3  1.5 NS
LVEDD (mm) 65  8 62  7 NS
LAD (mm) 46  9 40  7 0.01
Noradrenaline (pg/ml) 570  290 409  227 0.035
Drugs
ACE inhibitors 85% 83% NS
Digitalis 85% 90% NS
Diuretics 100% 70% NS
Beta-blocker* 31% 56% NS
Anti-arrhythmic drug
(Ib/III)†
30% (2/2) 17% (8/1) NS
*Use of beta-blocker (carvedilol), as scored at the last follow-up visit. †Class Ib
anti-arrhythmic drug mexiletine; class III amiodarone. Data are presented as the
mean value  SD or percentage of patients.
ACE  angiotensin-converting enzyme; LAD  left atrial dimension;
LVEDD left ventricular end-diastolic dimension; LVEF left ventricular ejection
fraction; NS  not significant; NYHA  New York Heart Association.
Figure 2. Plots of data of cardiac metaiodobenzylguanidine (MIBG) imaging in patients with chronic heart failure with and without cardiac events. H/M(e)
and H/M(d) denote the cardiac MIBG heart to mediastinum ratio (H/M) on the early and delayed images, respectively. Patients with cardiac events had
a significantly lower H/M(d) and higher washout rate (WR) than did those without cardiac events, although there was no significant difference in H/M(e)
between the two groups.
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those without cardiac events, although other time and
frequency domain parameters did not differ significantly
between the groups.
Prognostic analysis. On univariate analysis, WR, H/M on
the delayed image, LAD, plasma noradrenaline concentra-
tion, and n-VLFP were significantly associated with cardiac
events (Table 3). The risk ratio of cardiac events in patients
with an abnormal WR was 6.0 (95% confidence interval
[CI] 1.5 to 25.1), which was greater than the risk ratio (3.9
[95% CI 1.5 to 10.3]) in patients with abnormal n-VLFP.
Multivariate Cox analysis revealed that WR was the only
independent predictor of cardiac events.
Cardiac event–free rate curves, according to abnormal
WR and n-VLFP, are shown in Figures 3 and 4, respec-
tively. Cardiac events were significantly more frequently
observed in patients with than without abnormal WR (35%
vs. 6%, p  0.0012). Abnormal WR gave a sensitivity of
85%, a specificity of 62%, a positive predictive value of 35%,
and a negative predictive value of 94% for the prediction of
cardiac events in the chronic HF patients. On the other
hand, patients with abnormal n-VLFP had cardiac events
significantly more frequently than did those without abnormal
n-VLFP (42% vs. 11%, p 0.0028). Abnormal n-VLFP gave
a sensitivity of 61%, a specificity of 79%, a positive predictive
value of 42%, and a negative predictive value of 89% for the
prediction of cardiac events in the chronic HF patients.
The combination of abnormal WR and n-VLFP gave a
sensitivity of 54%, a specificity of 88%, a positive predictive
value of 54%, and a negative predictive value of 82% for the
identification of chronic HF patients at risk of cardiac
events. Predictive accuracy (82%) for the combination sig-
nificantly increased (p  0.05), compared with that for
abnormal WR (66%) (Table 4). Cardiac events were signif-
icantly more frequently observed in patients with both
abnormal WR and n-VLFP than in those with both normal
WR and n-VLFP (54% [7/13] vs. 4% [1/28], p  0.0001)
(Fig. 5).
DISCUSSION
In patients with chronic HF, cardiac adrenergic function is
characterized by a reduction in noradrenaline uptake and
Table 3. Univariate and Multivariate Cox Proportional Hazard Analyses for the Identification of
Patients With Chronic Heart Failure at Risk for Cardiac Events
Univariate Analysis Multivariate Analysis
p Value HR (95% CI) p Value HR (95% CI)
WR 0.0001 1.078 (1.041–1.116) 0.029 1.072 (1.007–1.14)
LAD 0.006 1.13 (1.036–1.236) 0.15 1.071 (0.975–1.175)
H/M(d) 0.01 0.067 (0.008–0.577) 0.42 3.994 (0.136–116.8)
NE 0.01 1.002 (1.000–1.004) 0.7 1.0 (0.998–1.003)
n-VLFP 0.047 0.924 (0.835–0.997) 0.53 0.972 (0.891–1.061)
CI confidence interval; H/M(d) heart to mediastinum metaiodobenzylguanidine uptake ratio on the delayed images; HR
hazard ratio; LAD  left atrial dimension; NE  plasma noradrenaline concentration; n-VLFP  normalized very-low-
frequency power; WR  washout rate of cardiac metaiodobenzylguanidine.
Table 2. Heart Rate Variability Measurements in Patients With
Chronic Heart Failure in Relation to Cardiac Events
With
Events
(n  13)
Without
Events
(n  52) p Value
Mean RR (ms) 810  44 822  201 NS
SDNN (ms) 120  43 120  32 NS
SDANN (ms) 112  44 110  32 NS
SDNN index (ms) 39  12 44  14 NS
rMSSD (ms) 28  7 27  14 NS
pNN50 (%) 6.1  4.5 7.5  8.4 NS
HRV index 17.8  4.9 20.8  9.2 NS
TP (ms2) 3,964  2,311 4,568  2,487 NS
ULFP (ms2) 2,639  1,611 2,777  1,509 NS
n-ULFP (%) 66.1  9.8 61.3  10.2 NS
VLFP (ms2) 969  665 1311  823 NS
n-VLFP (%) 23.2  6.4 29.1  9.0 0.03
LFP (ms2) 235  196 261  171 NS
n-LFP (%) 6.1  4.1 5.8  2.5 NS
HFP (ms2) 101  71 139  152 NS
n-HFP (%) 3.4  2.7 2.8  1.9 NS
LFP/HFP 2.5  1.9 2.9  1.9 NS
Data are presented as the mean value  SD.
HFP  high-frequency power; HRV  heart rate variability; LFP  low-
frequency power; Mean RR  mean duration of all normal to normal (NN) intervals;
n  normalized; pNN50  number of NN intervals differing by 50 ms from an
adjacent interval divided by the total number of NN intervals; rMSSD  square root
of the mean of the sum of squares of differences between adjacent NN intervals;
SDANN  standard deviation of averages of NN intervals in all 5-min segments;
SDNN  standard deviation of all NN intervals; SDNN index  mean of standard
deviations of all NN intervals for all 5-min segments; TP  total power; ULFP 
ultra-low frequency power; VLFP  very-low-frequency power.
Figure 3. The cardiac event-free rate curves by Kaplan-Meier analysis in
patients with chronic heart failure with and without an abnormal washout
rate (WR) (27%). The cardiac event-free rate was significantly lower in
patients with an abnormal WR than in those without it.
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acceleration of spillover in the myocardial adrenergic termi-
nals (23,24). Imaging with MIBG, an analogue of nor-
adrenaline that shares the same uptake pathway within the
myocardial adrenergic synapse, reflects cardiac adrenergic
nerve activity (10,11,24,25). It has been shown that cardiac
MIBG imaging has prognostic value in patients with
chronic HF (12-15), but a comparison with reduced HRV,
which indicates derangement in cardiac autonomic control
(5-9), has not yet been performed. Therefore, we attempted
to prospectively compare the prognostic value of cardiac
MIBG imaging with that of HRV analysis in patients with
chronic HF. This study demonstrated that cardiac MIBG
WR has higher prognostic value than HRV parameters, and
that the combination of abnormal WR and n-VLFP would
identify a higher-risk subset for cardiac events in chronic
HF.
Prognostic value of MIBG and HRV in chronic HF. An
accurate noninvasive assessment of cardiac sympathetic
nerve activity would be particularly important in the setting
of chronic HF because of the association between high
sympathetic activity in this condition and an adverse prog-
nosis (2). Cardiac MIBG imaging provides direct informa-
tion on the function and integrity of the presynaptic
sympathetic nerve endings (10,24,25). On the other hand,
HRV, which depends on postsynaptic signal transduction,
reflects the end-organ response of the sinus node. In
conditions characterized by marked, persistent sympathetic
activation, which is often observed in chronic HF, the sinus
node may drastically diminish its responsiveness to neural
inputs. The HRV parameters, tending toward very low
levels in chronic HF, might have a reduced dispersion, thus
limiting their possible statistical power in the regression
model. Furthermore, cardiac MIBG imaging may be useful
in the assessment of cardiac sympathetic alteration in
patients with a high incidence of ectopic activity, in whom
HRV analysis cannot always be performed reliably. There-
fore, in the present study, cardiac MIBG imaging had a
higher prognostic value than HRV analysis in patients with
chronic HF.
Cardiac MIBG WR. Uptake of MIBG in the myocardium
decreases with time, and there is evidence that MIBG WR
could be an index of noradrenaline spillover. There are
conflicting data on the relative prognostic values of MIBG
WR versus H/M on the delayed images (12-15). In the
present study, multivariate analysis showed that only MIBG
WR contributes to the estimation of clinical outcome,
although H/M on the delayed image was significantly lower
in patients with than in those without cardiac events. This
result is inconsistent with previous studies showing that
H/M has a powerful predictive value, whereas MIBG WR
does not (12,13). Different results concerning the predictive
value of WR may be due to differences in the method used
to calculate WR (application of background subtraction)
and the etiology of chronic HF. Metaiodobenzylguanidine
WR could reflect adrenergic activity more accurately in
patients with chronic HF, in whom denervation is sus-
pected, because WR is independent of the amount of
adrenergic neurons, whereas H/M is not. Therefore, in the
present study, MIBG WR was superior to H/M with regard
to the estimation of prognosis in patients with chronic HF.
Figure 5. The cardiac event-free rate curves by Kaplan-Meier analysis in
patients with chronic heart failure, according to a combination of abnormal
washout rate (WR) and normalized very-low-frequency power (n-VLFP).
The cardiac event-free rate was significantly lower in patients with both an
abnormal WR and n-VLFP than in those with both a normal WR and
n-VLFP.
Figure 4. The cardiac event-free rate curves by Kaplan-Meier analysis in
patients with chronic heart failure with and without abnormal normalized
very-low-frequency power (n-VLFP) (22). The cardiac event-free rate
was significantly lower in patients with abnormal n-VLFP than in those
without it.
Table 4. Prediction of Cardiac Events in Patients With Chronic
Heart Failure by a Combination of Abnormal Washout Rate
and Normalized Very-Low-Frequency Power
Abnormal
WR
Abnormal
n-VLFP
Abnormal
WR and n-VLFP
Sensitivity (%) 85 (11/13) 61 (8/13) 54 (7/13)
Specificity (%) 62 (32/52) 79 (41/52) 88* (46/52)
Positive predictive
value (%)
35 (11/31) 42 (8/19) 54 (7/13)
Negative predictive
value (%)
94 (32/34) 89 (41/46) 82 (46/52)
Predictive accuracy
(%)
66 (43/65) 75 (49/65) 82* (53/65)
*p  0.05 vs. abnormal WR. The numbers in parentheses are patient numbers.
n-VLFP  normalized very-low-frequency power; WR  washout rate of cardiac
metaiodobenzylguanidine.
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Effect of beta-blockade by carvedilol on cardiac MIBG
imaging. We assessed the effect of beta-blockade by carve-
dilol on the MIBG parameters in 21 study patients. The
WR significantly decreased (30.8 16.0% to 27.2 17.1%,
p  0.008) and H/M on the delayed images increased (1.68
 0.28 to 1.74  0.28, p  0.02) one year after the
administration of carvedilol, although there was no change
in H/M on the early images (1.78  0.20 to 1.79  0.29).
Furthermore, R-LVEF significantly increased one year after
carvedilol therapy (30.1  7.9% to 37.8  11.8%, p 
0.0001). The degree of decrease in MIBG WR roughly
correlated with the degree of increase in R-LVEF (r 
0.46, p  0.05). These findings were similar to those
reported in previous studies (26,27). These results suggest
that carvedilol would improve cardiac adrenergic function
by an increase in noradrenaline uptake and a reduction of
the spillover in cardiac adrenergic terminals and that the
improvement in LV function with carvedilol therapy might
be accompanied by an attenuation of activation of cardiac
adrenergic nerve function.
Heart rate variability in chronic HF. Previous studies
showed that time domain measurements of HRV, especially
SDNN, were independently associated with mortality (6-8).
However, in the present study, none of the time domain
measures of HRV were related to cardiac events. The
discrepancy may derive from differences in the severity of
chronic HF and the study end point, which we defined as
not only cardiac death but also hospitalization for worsening
chronic HF.
In the present study, on univariate analysis, n-VLFP
showed a significant association with cardiac events. Bigger
et al. (28) reported that VLFP after myocardial infarction
was strongly associated with a poor prognosis, although the
physiologic mechanism for this component has not been
fully identified. Very-low-frequency power may be influ-
enced by a number of factors other than autonomic balance,
such as thermoregulation, the renin-angiotensin system, or
peripheral chemoreceptors (29-31). Recently, it has been
shown that breathing disorders increase the spectral power
to the VLFP range in patients with chronic HF and
confound the use of HRV analysis (32). In the present
study, n-VLFP in patients with chronic HF was signifi-
cantly lower than that in normal control subjects with
normal breathing (27.9  8.8% vs. 32.3  5.1%, p  0.05).
Therefore, it appears that our study was not affected by this
confounding effect.
Study limitations. There are several limitations of this
study. First, medications used during follow-up may affect
MIBG uptake, HRV measurements, and clinical outcome.
There was a trend toward a decrease in the use of carvedilol
in patients with cardiac events, although the difference was
not statistically significant, which may be due to the small
sample size in the present study. However, even if the Cox
analysis were performed in the subgroups with and without
carvedilol therapy separately, the same result—that MIBG
WR was significantly associated with the cardiac events–was
obtained (p  0.035, hazard ratio 1.076 [95% CI 1.024 to
1.130] in subgroup with carvedilol therapy vs. p  0.02,
hazard ratio 1.074 [95% CI 1.010 to 1.142] in subgroup
without therapy). Second, there may be a problem in
quantifying the cardiac MIBG images. In the present study,
55 (85%) of 65 study patients had an exceedingly low H/M
on the early images (2.11, mean 2 SD of normal value:
2.43  0.16). This may introduce errors when drawing the
ROI manually on cardiac MIBG images of patients with
chronic HF. In the present study, two independent observ-
ers drew the ROI. The interobserver variation in counts per
pixel was within 1.2%. Thus, errors introduced by drawing
the ROI manually on the cardiac MIBG images are likely to
be subtle. Third, we excluded patients with atrial fibrilla-
tion, a pacemaker implant, frequent ectopic beats, or
insulin-dependent diabetes mellitus. Some of these condi-
tions could be associated with a worse prognosis and
therefore could introduce a bias—namely, selecting a sub-
group of patients with chronic HF with a lower event rate.
Fourth, in this study, we studied only stable outpatients who
had mild-to-moderate chronic HF. The results of our study
should not be generalized to inpatients with severe chronic
HF. Further study is needed to address this issue.
Conclusions. To the best of our knowledge, this is the first
study to show that the prognostic value of cardiac MIBG
imaging is more powerful than that of HRV analysis and
that the combination of abnormal WR and n-VLFP would
identify a higher-risk subset for cardiac events in patients
with mild-to-moderate chronic HF.
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